

CORRECTION

Open Access

# Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition

Erika Hamilton<sup>1</sup>, Kimberly Blackwell<sup>1</sup>, Amy C Hobeika<sup>2</sup>, Timothy M Clay<sup>3</sup>, Gloria Broadwater<sup>4</sup>, Xiu-Rong Ren<sup>5</sup>, Wei Chen<sup>5</sup>, Henry Castro<sup>3</sup>, Frederic Lehmann<sup>3</sup>, Neil Spector<sup>1</sup>, Junping Wei<sup>6</sup>, Takuya Osada<sup>6</sup>, H Kim Lyerly<sup>2</sup> and Michael A Morse<sup>1\*</sup>

## Corrections

In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors' list. Therefore the correct author list should be:

Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly and Michael A Morse.

Also the title of our original manuscript 'Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition' is also incorrect. The title should read: 'Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition'.

Journal of Translational Medicine regret any inconvenience that this inaccuracy might have caused.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contribution

All authors read and approved the final manuscript.

## Author details

<sup>1</sup>Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. <sup>2</sup>Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA. <sup>3</sup>GlaxoSmithKline Biologicals, Rixensart, Belgium. <sup>4</sup>Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA. <sup>5</sup>Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA. <sup>6</sup>Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA.

Received: 26 March 2013 Accepted: 26 March 2013

Published: 27 March 2013

## Reference

1. Hamilton, *et al*: Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. *J Transl Med* 2012, **10**:28.

doi:10.1186/1479-5876-11-82

**Cite this article as:** Hamilton *et al*: Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. *Journal of Translational Medicine* 2013 **11**:82.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



\* Correspondence: michael.morse@duke.edu

<sup>1</sup>Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA

Full list of author information is available at the end of the article